Crystallization of amorphous indomethacin during dissolution: Effect of processing and annealing

Molecular Pharmaceutics

Volumn 7, Issue 5, 2010, Pages 1406-1418

  Greco, Kristyn ^a   Bogner, Robin ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

ATR FTIR; flow through; glassy; phase conversion; Raman; Solution mediated phase transformation

Indexed keywords

INDOMETACIN;

ARTICLE; COOLING; CRYSTAL; CRYSTALLIZATION; DRUG SOLUBILITY; HUMAN; HUMIDITY; KINETICS; PERFORMANCE; PHASE TRANSITION; PRIORITY JOURNAL; PROCESSING; X RAY DIFFRACTION;

BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG STABILITY; INDOMETHACIN; MICROSCOPY, POLARIZATION; PHASE TRANSITION; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPECTRUM ANALYSIS, RAMAN; X-RAY DIFFRACTION;

EID: 77957739503     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp1000197     Document Type: Article

References (51)

1. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46 (1-3) 3-26 (Pubitemid 33653411)
2. Lobenberg, R.; Amidon, G. L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards Eur. J. Pharm. Biopharm. 2000, 50 (1) 3-12
3. Engel, G. L.; Farid, N. A.; Faul, M. M.; Richardson, L. A.; Winneroski, L. L. Salt form selection and characterization of LY333531 mesylate monohydrate Int. J. Pharm. 2000, 198 (2) 239-247
4. Hancock, B. C.; Parks, M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 2000, 17 (4) 397-404
5. Chen Linna, R.; Wesley James, A.; Bhattachar, S.; Ruiz, B.; Bahash, K.; Babu Suresh, R. Dissolution behavior of a poorly water soluble compound in the presence of Tween 80 Pharm. Res. 2003, 20 (5) 797-801
6. Debnath, S.; Predecki, P.; Suryanarayanan, R. Use of Glancing Angle X-Ray Powder Diffractometry to Depth-Profile Phase Transformations During Dissolution of Indomethacin and Theophylline Tablets Pharm. Res. 2004, 21 (1) 149-159
7. Murphy, D.; Rodriguez-Cintron, F.; Langevin, B.; Kelly, R. C.; Rodriguez-Hornedo, N. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder Int. J. Pharm. 2002, 246 (1-2) 121-134
8. Rodriguez-Hornedo, N.; Lechuga-Ballesteros, D.; Wu, H. J. Phase transition and heterogeneous/epitaxial nucleation of hydrated and anhydrous theophylline crystals Int. J. Pharm. 1992, 85 (1-3) 149-162
9. Rodriguez-Hornedo, N.; Murphy, D. Significance of Controlling Crystallization Mechanisms and Kinetics in Pharmaceutical Systems J. Pharm. Sci. 1999, 88 (7) 651-660
10. Rodriguez-Hornedo, N.; Murphy, D. Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph J. Pharm. Sci. 2004, 93 (2) 449-460
11. Kaushal, A. M.; Gupta, P.; Bansal, A. K. Amorphous drug delivery systems: Molecular aspects, design, and performance Crit. Rev. Ther. Drug Carrier Syst. 2004, 21 (3) 133-193
12. Cardew, P. T.; Davey, R. J. The kinetics of solvent-mediated phase transformations Proc. R. Soc. London, Ser. A 1985, 398 (1815) 415-428
13. Aaltonen, J.; Heinanen, P.; Peltonen, L.; Korteiarvi, H.; Tanninen, V. P.; Christiansen, L.; Hirvonen, J.; Yliruusi, J.; Rantanen, J. In situ measurement of solvent-mediated phase transformations during dissolution testing J. Pharm. Sci. 2006, 95 (12) 2730-2737
14. Anquetil, P. A.; Brenan, C. J. H.; Marcolli, C.; Hunter, I. W. Laser Raman spectroscopic analysis of polymorphic forms in microliter fluid volumes J. Pharm. Sci. 2003, 92 (1) 149-160
15. Brittain, H. G. Fluorescence studies of the transformation of carbamazepine anhydrate form III to its dihydrate phase J. Pharm. Sci. 2004, 93 (2) 375-383
16. Caillet, A.; Puel, F.; Fevotte, G. In-line monitoring of partial and overall solid concentration during solvent-mediated phase transition using Raman spectroscopy Int. J. Pharm. 2006, 307 (2) 201-208
17. Tian, F.; Zeitler, J. A.; Strachan, C. J.; Saville, D. J.; Gordon, K. C.; Rades, T. Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy J. Pharm. Biomed. Anal. 2006, 40 (2) 271-280
18. Wang, F.; Wachter, J. A.; Antosz, F. J.; Berglund, K. A. An Investigation of Solvent-Mediated Polymorphic Transformation of Progesterone Using in Situ Raman Spectroscopy Org. Process Res. Dev. 2000, 4 (5) 391-395
19. Zhang, G. G. Z.; Law, D.; Schmitt, E. A.; Qiu, Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms Adv. Drug Delivery Rev. 2004, 56 (3) 371-390
20. Crowley, K. J.; Zografi, G. Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability J. Pharm. Sci. 2002, 91 (2) 492-507
21. Fukuoka, E.; Makita, M.; Yamamura, S. Some physicochemical properties of glassy indomethacin Chem. Pharm. Bull. 1986, 34 (10) 4314-21
22. Taylor, L. S.; Zografi, G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions Pharm. Res. 1997, 14 (12) 1691-1698
23. Taylor, L. S.; Zografi, G. The quantitative analysis of crystallinity using FT-Raman spectroscopy Pharm. Res. 1998, 15 (5) 755-761
24. Heinz, A.; Savolainen, M.; Rades, T.; Strachan, C. J. Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy Eur. J. Pharm. Sci. 2007, 32 (3) 182-192
25. Hedoux, A.; Paccou, L.; Guinet, Y.; Willart, J.-F.; Descamps, M. Using the low-frequency Raman spectroscopy to analyze the crystallization of amorphous indomethacin Eur. J. Pharm. Sci. 2009, 38 (2) 156-164
26. Savolainen, M.; Kogermann, K.; Heinz, A.; Aaltonen, J.; Peltonen, L.; Strachan, C.; Yliruusi, J. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy Eur. J. Pharm. Biopharm. 2009, 71 (1) 71-79
27. Wu, T.; Sun, Y.; Li, N.; De Villiers, M. M.; Yu, L. Inhibiting Surface Crystallization of Amorphous Indomethacin by Nanocoating Langmuir 2007, 23 (9) 5148-5153
28. Wu, T.; Yu, L. Surface Crystallization of Indomethacin Below Glass Transition Temperature Pharm. Res. 2006, 23 (10) 2350-2355
29. Andronis, V.; Yoshioka, M.; Zografi, G. Effects of sorbed water on the crystallization of indomethacin from the amorphous state J. Pharm. Sci. 1997, 86 (3) 346-351
30. Bahl, D.; Bogner, R. H. Amorphization of Indomethacin by Co-Grinding with Neusilin US2: Amorphization Kinetics, Physical Stability and Mechanism Pharm. Res. 2006, 23 (10) 2317-2325
31. Murdande, S. B.; Pikal, M. J.; Shanker, R. M.; Bogner, R. H. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis J. Pharm. Sci. 2010, 99 (3) 1254-1264
32. Bogner, R. H.; Bergman, T. L.; Greco, K.; Michaels, D. J.; Chawarski, S. J. Flow-through apparatus for microscopic investigation of dissolution of pharmaceutical solids. United States Patent Application 2008138261, 2008.
33. Greco, K.; Bergman, T. L.; Bogner, R. H. Design and Characterization of a Laminar Flow-Through Dissolution Apparatus: Comparison of Hydrodynamic Conditions to Those of Common Dissolution Techniques. Pharm. Dev. Technol. 2010, doi: 10.3109/10837450903499341.
34. Baxter, J. L.; Kukura, J.; Muzzio, F. J. Hydrodynamics-induced variability in the USP apparatus II dissolution test Int. J. Pharm. 2005, 292 (1-2) 17-28
35. Kukura, J.; Baxter, J. L.; Muzzio, F. J. Shear distribution and variability in the USP Apparatus 2 under turbulent conditions Int. J. Pharm. 2004, 279 (1-2) 9-17
36. Abrahamsson, B.; Pal, A.; Sjoeberg, M.; Carlsson, M.; Laurell, E.; Brasseur, J. G. A Novel in Vitro and Numerical Analysis of Shear-Induced Drug Release from Extended-Release Tablets in the Fed Stomach Pharm. Res. 2005, 22 (8) 1215-1226
37. Pal, A.; Indireshkumar, K.; Schwizer, W.; Abrahamsson, B.; Fried, M.; Brasseur James, G. Gastric flow and mixing studied using computer simulation Proc. Biol. Sci. 2004, 271 (1557) 2587-94
38. Cox, P. J.; Manson, P. L. γ-Indomethacin at 120 K Acta Crystallogr., Sect. E: Struct. Rep. Online 2003, E59 (7 o986-o988
39. Shah, A. C.; Nelson, K. G. Evaluation of a convective diffusion drug dissolution rate model J. Pharm. Sci. 1975, 64 (9) 1518-20
40. Geankoplis, C. J. Transport Processes and Unit Operations; Allyn and Bacon: 1978; 650 pp.
41. Neervannan, S.; Reinert, J. D.; Stella, V. J.; Southard, M. Z. A numerical convective-diffusion of neutral compounds under laminar flow conditions Int. J. Pharm. 1993, 96 (1-3) 167-174
42. Curvature in the cumulative amount dissolved vs time curve has also been noted for dissolution of poorly soluble compounds that do not undergo solvent mediated phase transformation. (33) This curvature is not as pronounced as the curvature attributed to solvent mediated phase transformation and is hypothesized to be due to surface smoothing.
43. Sun, W.; Larive, C. K.; Southard, M. Z. A mechanistic study of danazol dissolution in ionic surfactant solutions J. Pharm. Sci. 2003, 92 (2) 424-435
44. Grijseels, H.; De Blaey, C. J. Dissolution at porous interfaces. V. Pore effects in a parallel-plate dissolution cell Int. J. Pharm. 1983, 16 (3) 295-304 (Pubitemid 13010889)
45. Chamarthy, S. P.; Pinal, R. The nature of crystal disorder in milled pharmaceutical materials Colloids Surf., A 2008, 331 (1-2) 68-75
46. Feng, T.; Bates, S.; Carvajal, M. T. Toward understanding the evolution of griseofulvin crystal structure to a mesophase after cryogenic milling Int. J. Pharm. 2009, 367 (1-2) 16-19
47. Bates, S.; Zografi, G.; Engers, D.; Morris, K.; Crowley, K.; Newman, A. Analysis of Amorphous and Nanocrystalline Solids from Their X-Ray Diffraction Patterns Pharm. Res. 2006, 23 (10) 2333-2349
48. Bhugra, C.; Shmeis, R.; Pikal, M. J. Role of mechanical stress in crystallization and relaxation behavior of amorphous indomethacin J. Pharm. Sci. 2008, 97 (10) 4446-4458
49. Okumura, T.; Ishida, M.; Takayama, K.; Otsuka, M. Polymorphic transformation of indomethacin under high pressures J. Pharm. Sci. 2006, 95 (3) 689-700
50. Langkilde, F. W.; Sjoeblom, J.; Tekenbergs-Hjelte, L.; Mrak, J. Quantitative FT-Raman analysis of two crystal forms of a pharmaceutical compound J. Pharm. Biomed. Anal. 1997, 15 (6) 687-696
51. The laser spot size for this instrument and the 20× objective is approximately 10 μm, which does not capture enough surface area to describe the entire compact surface. Others have remedied this problem for quantification of solid forms using Raman spectroscopy by using rotating stages. (50) This approach was not used here since quantification by Raman microscopy was not the intention for this study.